This leading event provides a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.

The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.

FEATURED SPEAKERS INCLUDE:

Richard Bax, Senior Partner, TranScrip Partners

Lloyd Czaplewski, Director, Chemical Biology Ventures

Mair Powell, Senior clinical assessor, MHRA

Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)